Evaluating the Efficacy of ERG Targeted Therapy In Vivo for Prostate Tumors
Abstract
The proposed research will examine the suitability of ERG as a target for prostate cancer therapy by using novel transgenic mice. Prostate cancer is a large health problem in the United States. Recent efforts to classify distinct molecular subtypes of prostate cancer have shown that >50% of prostate cancers possess a chromosomal translocation involving the ERG oncogene. I hypothesized that ERG can serve as an effective molecular therapeutic target for prostate tumors using novel prostate tumor mouse models. During this third year of support we have not been able to adhere to our Statement of Work - Task#2 or Task#3. We were successful at completing Task#1, but characterization of ERG expression from our prostate inducible mouse model did not demonstrate any detectable prostate specific ERG expression at the protein level. Data from another project using the ARR2PB-tTA line has lead us to believe that the level of expression from the ARR2PB-tTA line is low and perhaps insufficient for the in vivo experiments described in our proposal. To remedy this issue with low prostate specific expression we proposed to re-start Task #1 of the project with the new prostate specific TET driver mouse, Hoxb13-rtTA, but difficulties with breeding have hampered our progress. We have overcome these issues and have been able to see robust prostate specific expression using this Hoxb13-rtTA driver. We are now in the process of reinitiating our studies on the ability of ERG to collaborate with AKT1 with these new mice, Hoxb13-rtTA/ tetO-ERG.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2014
- Accession Number
- ADA603144
Entities
People
- Phuoc T. Tran
Organizations
- Johns Hopkins University